GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Unity Biotechnology Inc (NAS:UBX) » Definitions » Effective Interest Rate on Debt %

Unity Biotechnology (Unity Biotechnology) Effective Interest Rate on Debt % : 0.00% (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Unity Biotechnology Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Unity Biotechnology's annualized positive value of Interest Expense for the quarter that ended in Mar. 2024 was $0.00 Mil. Unity Biotechnology's average total debt for the quarter that ended in Mar. 2024 was $24.80 Mil. Therefore, Unity Biotechnology's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2024 was 0.00%.


Unity Biotechnology Effective Interest Rate on Debt % Historical Data

The historical data trend for Unity Biotechnology's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Unity Biotechnology Effective Interest Rate on Debt % Chart

Unity Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Effective Interest Rate on Debt %
Get a 7-Day Free Trial - 2.03 5.32 6.69 6.33

Unity Biotechnology Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.24 8.71 5.57 0.02 -

Competitive Comparison of Unity Biotechnology's Effective Interest Rate on Debt %

For the Biotechnology subindustry, Unity Biotechnology's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Unity Biotechnology's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Unity Biotechnology's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Unity Biotechnology's Effective Interest Rate on Debt % falls into.



Unity Biotechnology Effective Interest Rate on Debt % Calculation

Unity Biotechnology's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2022 )+Total Debt  (A: Dec. 2023 ))/ count )
=-1  *  -2.452/( (50.458+26.99)/ 2 )
=-1  *  -2.452/38.724
=6.33 %

where

Total Debt  (A: Dec. 2022 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=37.882 + 12.576
=50.458

Total Debt  (A: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=23.539 + 3.451
=26.99

Unity Biotechnology's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2024 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Dec. 2023 )+Total Debt  (Q: Mar. 2024 ))/ count )
=-1  *  0/( (26.99+22.606)/ 2 )
=-1  *  0/24.798
=0.00 %

where

Total Debt  (Q: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=23.539 + 3.451
=26.99

Total Debt  (Q: Mar. 2024 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=22.606 + 0
=22.606

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Mar. 2024) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.


Unity Biotechnology  (NAS:UBX) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


Unity Biotechnology Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Unity Biotechnology's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.


Unity Biotechnology (Unity Biotechnology) Business Description

Industry
Traded in Other Exchanges
Address
285 East Grand Avenue, South San Francisco, CA, USA, 94080
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases.
Executives
Anirvan Ghosh director, officer: Chief Executive Officer C/O UNITY BIOTECHNOLOGY, INC., 285 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Jamie Dananberg officer: Chief Medical Officer 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Michael P. Samar director C/O ASSEMBLY BIOSCIENCES, INC., 11711 N. MERIDIAN ST. SUITE 310, CARMEL IN 46032
Alexander Hieu Nguyen officer: See Remarks C/O UNITY BIOTECHNOLOGY, INC., 285 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Nathaniel E David director, officer: President C/O KYTHERA BIOPHARMACEUTICALS, INC., 27200 WEST AGOURA ROAD, SUITE 200, CALABASAS CA 91301
Gilmore Neil O'neill director 215 FIRST STREET, CAMBRIDGE MA 02142
Alexander Azoy officer: See Remarks 30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Lynne Marie Sullivan officer: See Remarks C/O SOLID BIOSCIENCES, LLC, 141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139
Robert Nelsen director 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Graham K Cooper director C/O RECEPTOS, INC., 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Paul L Berns director 11080 CIRCLEPOINT RD., STE, 200, WESTMINSTER CO 80020
Camille D Samuels director 2463 JACKSON ST., SAN FRANCISCO CA 94115
Kristina Burow director 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
David L. Lacey director 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Dan Marquess officer: Chief Scientific Officer 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005

Unity Biotechnology (Unity Biotechnology) Headlines